Fig. 3: Targeting the IL-17/IL-23 axis with monoclonal antibodies is effective in patients with Darier disease. | Nature Communications

Fig. 3: Targeting the IL-17/IL-23 axis with monoclonal antibodies is effective in patients with Darier disease.

From: Th17-associated cytokines IL-17 and IL-23 in inflamed skin of Darier disease patients as potential therapeutic targets

Fig. 3

a Cutaneous improvement after personalized targeted antibody therapy. Clinical images of guselkumab (upper, PAT1) and secukinumab (central and lower, PAT2 and PAT9) treated patients before, 3–4 and 11–12 months after initiation of antibody therapy. b Clinical improvement of DD patients during therapy as determined by the Investigator’s Global Assessment (IGA) score.

Back to article page